Cogent Biosciences Inc
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well… Read more
Cogent Biosciences Inc (COGT) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.124x
Based on the latest financial reports, Cogent Biosciences Inc (COGT) has a cash flow conversion efficiency ratio of -0.124x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-79.11 Million) by net assets ($636.37 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cogent Biosciences Inc - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Cogent Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Cogent Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cogent Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shanghai Fudan Microelectronics Group Co Ltd
SHG:688385
|
0.034x |
|
China Merchants Energy Shipping Co Ltd
SHG:601872
|
0.054x |
|
Sagax AB Series B
LSE:0QDX
|
0.028x |
|
Rightmove plc
PINK:RTMVF
|
1.469x |
|
BERKELEY GR.HL LS-054141
F:42BB
|
N/A |
|
Federal Home Ln Mtg
OTCQB:FMCKM
|
0.037x |
|
SGH Ltd
AU:SGH
|
0.144x |
|
GALDERMA GROUP AG
NYSE:GALDY
|
N/A |
Annual Cash Flow Conversion Efficiency for Cogent Biosciences Inc (2015–2025)
The table below shows the annual cash flow conversion efficiency of Cogent Biosciences Inc from 2015 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $636.37 Million | $-264.44 Million | -0.416x | +48.75% |
| 2024-12-31 | $256.29 Million | $-207.79 Million | -0.811x | -36.06% |
| 2023-12-31 | $257.80 Million | $-153.62 Million | -0.596x | -28.45% |
| 2022-12-31 | $255.74 Million | $-118.64 Million | -0.464x | -69.09% |
| 2021-12-31 | $214.18 Million | $-58.76 Million | -0.274x | -79.59% |
| 2020-12-31 | $234.67 Million | $-35.85 Million | -0.153x | +88.31% |
| 2019-12-31 | $31.76 Million | $-41.51 Million | -1.307x | -142.32% |
| 2018-12-31 | $60.23 Million | $-32.49 Million | -0.539x | +40.91% |
| 2017-12-31 | $28.30 Million | $-25.84 Million | -0.913x | -156.53% |
| 2016-12-31 | $52.39 Million | $-18.64 Million | -0.356x | -239.62% |
| 2015-12-31 | $69.52 Million | $17.72 Million | 0.255x | -- |